Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Not yet recruiting
This trial aims to compare the benefits and risks of tisagenlecleucel to blinatumomab or
inotuzumab in adult patients with relapsed or refractory ALL. This trial investigates
tisagenlecleucel as an additional treatment option for this patient population with high
unmet medical need.
MT2017-45 :CAR-T Cell Therapy for Heme Malignancies
Not yet recruiting
Masonic Cancer Center, University of Minnesota
This is a phase II study of FDA-approved CAR-T products for patients with hematologic
malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall
remission rate, safety events and other endpoints will be calculated for Arm A and B
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.